Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis

30 May 2023

Abstract excerpt

Introduction: Multiple Sclerosis (MS) has a complex pathophysiology that involves genetic and environmental factors. DNA methylation (DNAm) is one epigenetic mechanism that can reversibly modulate gene expression. Cell specific DNAm changes have been associated with MS, and some MS therapies such as dimethyl fumarate can influence DNAm. Interferon Beta (IFNβ), was one of the first disease modifying therapies in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to interferon and immune responses
Share to Multiple Sclerosis Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37325639
DOI: 10.3389/fimmu.2023.1162796

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosisPMID 37325639Read ↗

GEO Data Sets Analysis On Mechanism of Action of IFNβ-1a Treatment in Multiple SclerosisSemantic proximity Read ↗

Global DNA Methylation and Hydroxymethylation Levels in PBMCs Are Altered in RRMS Patients Treated with IFN-β and GA—A Preliminary StudySemantic proximity Read ↗

Time course transcriptomics of IFNB1b drug therapy in multiple sclerosisSemantic proximity Read ↗

Epigenetic and genetic insights for tailored therapeutic strategies in multiple sclerosis.Semantic proximity Read ↗

Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.Semantic proximity Read ↗

Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosisSemantic proximity Read ↗

Pharmacogenetics of multiple sclerosisSemantic proximity Read ↗

An RNA Profile Identifies Two Subsets of Multiple Sclerosis Patients Differing in Disease ActivitySemantic proximity Read ↗

Long-Term Genome-Wide Blood RNA Expression Profiles Yield Novel Molecular Response Candidates for IFN-β-1b Treatment in Relapsing Remitting MSSemantic proximity Read ↗

Gene expression analysis of interferon-β treatment in multiple sclerosisSemantic proximity Read ↗

Systems Analysis of Immune Changes after B-cell Depletion in Autoimmune Multiple SclerosisSemantic proximity Read ↗

Search for Specific Biomarkers of IFNβ Bioactivity in Patients with Multiple SclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.